





# Single Anastomosis Duodenal Switch versus Roux-en-Y Gastric Bypass in patients with BMI ≥ 50 kg/m2: A Multi-centered comparative analysis

Karl Hage MD, Romulo Lind MD, Mohammad Al Kordi MD, Muhammad Ghanem MD, Kamal Abi Mosleh MD, Marita Salame MD, Muhammad A. Jawad MD, Michael L. Kendrick MD, Andre F. Teixeira MD, Omar M. Ghanem MD

Mayo Clinic, Rochester, MN, United States




## **Disclosures**

The authors have no potential conflict of interest to report







Outcomes of Roux-en-Y gastric bypass in the super obese: comparison of body mass index 50-60 kg/m(2) and≥60 kg/m(2) with the morbidly obese

Rena C Moon 1, Lars Nelson 1, Andre F Teixeira 1, Muhammad A Jawad 2

Affiliations + expand

PMID: 26826916 DOI: 10.1016/j.soard.2015.10.072

## Does BMI Matter? A 10-Year Single Institutional Experience on 571 Bariatric Surgery Patients With BMI >50 kg/m 2


Joseph N Badaoui <sup>1</sup>, Justin W Maroun <sup>1</sup>, Omobolanle O Oyefule <sup>1</sup>, Jay Mandrekar <sup>2</sup>, Travis J McKenzie <sup>1</sup>, Michael L Kendrick <sup>1</sup>, Todd A Kellogg <sup>1</sup>, Omar M Ghanem <sup>1</sup>

Affiliations + expand

PMID: 35583523 DOI: 10.1097/SLE.0000000000001063












SADI-S, in its early adoption stage, has a higher incidence of perioperative complications than RYGB<sup>1</sup>.

	All Cohort (Pre-Match)	-		Match Cohort		
	Roux-en-Y	SADI		Roux-en-Y	SADI	
Clavien-Dindo Class	24452	255	p-value	1275	255	p-value
Grade 1						
Superficial Incisional SSI	153 (0.6%)	1 (0.4%)	1.0	8 (0.6%)	1 (0.4%)	1.0
Grade 2						
UTI	103 (0.4%)	1 (0.4%)	1.0	7 (0.5%)	1 (0.4%)	1.0
Pneumonia	82 (0.3%)	3 (1.2%)	0.06	7 (0.5%)	3 (1.2%)	0.22
Venous Thrombosis	39 (0.2%)	1 (0.3%)	0.34	3 (0.2%)	1 (0.3%)	0.52
Transfusion	245 (1.0%)	4 (1.6%)	0.33	9 (0.7%)	4 (1.6%)	0.25
Grade 3a		0 22		2 (2		
Deep Incisional SSI	17 (0.1%)	0 (0%)	1.0	1 (0.1%)	0 (0%)	1.0
Grade 3b	0.0000000000	10.000.000		A-00000000	a - thank	
Pulmonary Embolism	44 (0.2%)	0 (0%)	1.0	5 (0.4%)	0 (0%)	0.60
Grade 4a	300 000 <b>*</b> 100 300 10 <b>*</b> 10 1			Company of the Compan	0.000	
Acute Renal Failure	21 (0.1%)	1 (0.4%)	0.20	0 (0%)	1 (0.4%)	0.17
Cardiac Arrest	9 (0%)	1 (0.4%)	0.10	0 (0%)	1 (0.4%)	0.17
Myocardial Infarct	6 (0%)	1 (0.4%)	0.07	0 (0%)	1 (0.4%)	0.17
Progressive Renal Failure	9 (0%)	1 (0.4%)	0.10	1 (0.1%)	1 (0.4%)	0.31
Grade 4b						
Ventilator	23 (0.1%)	1 (0.4%)	0.22	1 (0.1%)	1 (0.4%)	0.31
Organ Space SSI	95 (0.4%)	5 (2.0%)	< 0.01	7 (0.5%)	5 (2.0%)	0.04
Anastomosis Leak	58 (0.2%)	5 (2.0%)	< 0.01	4 (0.3%)	5 (2.0%)	0.01
Sepsis	26 (0.1%)	2 (0.8%)	0.03	0 (0%)	2 (0.8%)	0.03
Septic Shock	20 (0.1%)	2 (0.8%)	0.02	1 (0.1%)	2 (0.8%)	0.07
Unplanned ICU Admissions	151 (0.6%)	3 (1.2%)	0.21	5 (0.4%)	3 (1.2%)	0.13
Grade 5	10 50	30 %	1054460	(20. 40		500,000
Death	47 (0.2%)	1 (0.4%)	0.39	1 (0.1%)	1 (0.4%)	0.31







In the long term (10 years), SADI-S offers satisfactory weight loss and comorbidities resolution<sup>1</sup>.





## **Hypothesis and Aims**



#### Question:

 Is SADIS an efficient and safe bariatric surgery for patients with BMI ≥ 50 kg/m2 ?

#### Aims:

 Our study aims to comprehensively compare the safety and efficacy of SADI-S and RYGB for patients with a preoperative BMI ≥ 50 kg/m2.





## **Methods**

- Multicentered retrospective cohort study.
- Inclusion Criteria:
  - 1. Adult patients with preoperative BMI ≥ 50 kg/m²
  - 2. Underwent RYGB or SADI-S from 2008-2020
- Exclusion Criteria:
  - 1. No follow-up data
  - 2. Pediatric population





## Results: Demographics and Baseline Characteristics


	Bariatric	Procedure	ц		
Patient Demographics	RYGB (N=343)	SADI-S (N=120)	Total (N=463)	p-value	
Age at procedure, years (SD)	44.9 (13.1)	41.4 (9.9)	43.9 (12.4)	0.00111	
Sex, Female (%)	256 (74.6)	81 (67.5)	337 (72.8)	$0.131^{2}$	
Race, White (%)	315 (91.8)	80 (66.7)	395 (85.3)	< 0.001 <sup>2</sup>	
BMI Pre-op, kg/m <sup>2</sup> (SD)	56.8 (6.1)	59.9 (8.2)	57.6 (6.8)	< 0.0011	
Obesity-related comorbidities					
Sleep Apnea (%)	255 (74.3)	56 (46.7)	311 (67.2)	< 0.001 <sup>2</sup>	
Hypertension (%)	189 (55.1)	68 (55.5)	257 (55.5)	$0.088^{2}$	
GERD (%)	183 (53.4)	26 (21.7)	209 (45.1)	< 0.001 <sup>2</sup>	
Hyperlipidemia (%)	174 (50.7)	34 (28.3)	208 (44.9)	< 0.001 <sup>2</sup>	
Diabetes Mellitus (%)	124 (36.2)	39 (32.5)	163 (35.2)	$0.520^{2}$	

1Equal variance two sample t-test; 2Chi-Square test





# **Results: Operative Outcomes**








## Results: Weight loss Outcomes (%TWL)

#### **SADI-S vs RYGB:**

12 Mo – **35.6%** vs 31.9%

24 Mo – **41.2%** vs 31.8%

60 Mo – **40.7%** vs 25.8%







### Conclusion

- SADI-S was associated with higher and sustained midand long-term weight-loss results compared to RYGB for patients with BMI ≥ 50 kg/m².
- Both SADI-S and RYGB presented a similar early and late safety profile with a relatively low one-year mortality rate.



Thank you for your attention! Questions or Comments?